Register for Patients With Diabetic Foot Syndrome and Critical Limb Ischemia

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01599442

Acronym

August-1

Enrollment

123

Registered

2012-05-16

Start date

2010-06-30

Completion date

2013-07-31

Last updated

2014-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Limb Ischemia, Diabetic Foot, Type 2 Diabetes Mellitus

Brief summary

Diabetic foot syndrome (DFS) is a disease caused by neurogenic (concerning the nervous system), vascular, mechanic and metabolic factors, which are further complicated by an impairment of the immune system and a corresponding increase in the risk for infections. Results from clinical trials about the efficacy of interventions aimed at reducing the number of patient-relevant end points are of limited comparability due to the heterogenity of patient characteristics. By their very nature, randomized clinical trials (RCT) can only focus on a limited section of the wide range of possible intervention regimes. In clinical practice, however, a number of patients with dfs will never have been part of a clinical trial. Furthermore, there are only very few contemporary registers for this indication from which conclusions with regard to the comparative merits of different therapeutic strategies may be drawn. The register was conceived to find out to which extent RCT patients are representative for the overall patient collective with dfs and critical limb ischemia and to evaluate the therapeutic success of other treatment strategies. An RCT to assess the efficacy of urokinase versus placebo is imbedded in the register.

Detailed description

August-1 is a register to find out to which extent RCT patients are representative for the overall patient collective with dfs and critical limb ischemia and to evaluate the therapeutic success of other treatment strategies. An RCT to assess the efficacy of urokinase versus placebo is imbedded in the register.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* diabetic patients with dfs and critical limb ischemia * age 18 and older

Exclusion criteria

* less than 1 year life expectancy * prior major amputation * planned major expectation * prior treatment of the current episode of dfs with urokinase * mechanical heart valve replacement * cerebral event with changes in CT during the last three months * non-remediated proliferating retinopathy * uncontrolled hypertension (systolic \> 180 mmHg, diastolic \> 100 mmHg) * hemorrhagic diathesis (spontaneous quick value \< 50%, spontaneous ptt \> 40 sec, thrombocytes \< 100 gpt/l) * acute gastrointestinal bleeding or ulcers during the last 4 weeks * prior reverse bypass operation * concomitant participation in other clinical trials * insufficient compliance * premenopausal women not using a safe method of contraception (i. e. IUD, hormone implants, hormone depot injection, combined pill (estrogens and gestagens), vaginal ring or vasectomized partner).

Design outcomes

Primary

Measure	Time frame
duration of survival without major amputation	to be assessed after 12 months observation

Secondary

Measure	Time frame
major amputation	after 12 months observation
total mortality	after 12 months observation

Countries

Germany

Outcome results